InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,537.02
(
0.51%
)
US TECH 100
19,641.60
(
0.83%
)
Dow Jones
39,308.00
(
-0.06%
)
Brent Oil
87.33
(
0.48%
)
Bitcoin
58,309.17
(
-3.09%
)
Post# of 45771
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

sanddollar

Send PM Follow Ignore
Followers 1
Posts 2165
Boards Moderated 0
Alias Born 12/15/2001

sanddollar

Re: None

Thursday, 04/10/2008 2:54:14 PM

Thursday, April 10, 2008 2:54:14 PM

Post# of 45771
Oh, I almost forgot: here's the conclusion of the much touted Mott study:

Conclusion: A tabletop EPS device demonstrated acceptable sensitivity and specificity for validating the identity and concentrations of selected high-risk i.v. medications compounded for pediatric patients. The device may help prevent clinically important medication errors caused by inaccurate compounding.

http://pt.wkhealth.com/pt/re/ajhp/abstract.00043627-200801010-00015.htm;jsessionid=H2fds1LKx5r7bLgmJx3HVyPT2VGZRXfSKw0vLNrfbghndWBLMnnj!624628136!181195629!8091!-1

The [ValiMed] device demonstrated acceptable sensitivity ...

The device may help prevent ...

Hardly worthy of a standing ovation.

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up